摘要
目的:探讨短程口服特比萘芬加外用联苯苄唑乳膏治疗中、重度足癣的疗效和安全性。方法:采用开放、随机对照的平行研究。将临床和真菌镜检确诊的中、重度足癣患者随机分入A、B、C 3组,A组口服特比萘芬片7 d联合外用联苯苄唑乳膏14 d;B组常规口服特比萘芬片,疗程14 d;C组常规外用联苯苄唑乳膏,疗程4周。对各组的临床疗效、安全性及治疗费用进行分析。结果:①临床疗效:停药时A组治愈率为52.00%,与B组(14.29%)相比较,差异有显著性;停药后2周和4周时A组治愈率分别为90.00%和88.00%,与C组(63.83%、59.57%)比较差异有显著性。②真菌学疗效:停药后4周时A组真菌清除率为92.00%,与C组(63.83%)比较差异有显著性。③安全性评价:治疗结束时不良反应发生率3组间没有显著性差异。④治疗费用:A组人均治疗费用较B组降低37.49%。结论:短程口服特比萘芬加外用联苯苄唑乳膏较单用口服药或外用药治疗中、重足癣疗效好、起效快、安全性高,且费用相对较低。
Aim： To evaluate the efficacy and safety of short-term oral terbinafine combined with topical bifonazole cream treating moderate.and severe tinea pedis. Methods： An open-labelled, randomized, controlled and parallel clinical trial was carried out. One hundred and fifty patients with clinical and myco- logical diagnosis of moderate to severe tinea pedis were divided into three groups to receive 7 days of oral terbinafine （Lamisil） combined with 14 days of topical bifonazole （MeiKe） cream （group A）, or oral terbinafine （Lamisil） for 14 days （group B）, or topical bifonazole （MeiKe） cream for4 weeks （group C）. Efficacy, safety and cost were compared. Results： ① Clinical cure rate ： At the end point the clinical cure rate in group A was significantly higher than in group B （52. 00% vs 14. 29% ） ; At week 2 and week 4 the clinical cure rates in group A were significantly higher than in group C （90. 00% and 88.00% in group A vs 63.83% and 59.57% in group C）. （2） Mycological cure rate： At week 4, the mycological cure rate in group A was significantly higher than in group C （92. 00% vs 63.83% ）. （3） Safety： There was no statistical difference in side-effect rate among these 3 groups. （4） Cost： The cost of group A was lower than group B by 37.49%. Conclusion： Short-term oral terbinafine combined with topical bifonazole cream was much more effective, safe and lower cost in the treatment of moderate to severe tinea pedis.
出处
《暨南大学学报（自然科学与医学版）》
CAS
CSCD
北大核心
2008年第4期409-411,共3页
Journal of Jinan University(Natural Science & Medicine Edition)
关键词
特比萘芬
联苯苄唑
足癣治疗
terbinafine
bifonazole
tinea pedis treatment
